Good Start Genetics Raises $14M in Series B Financing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Good Start Genetics today announced the initial closing of a Series B Preferred Stock financing that raised $14 million.

The funds will be used to support commercialization efforts of the Cambridge, Mass.-based firm's screening tests and to support R&D work to develop its proprietary platform technology for future applications, it said.

Existing investors OrbiMed Advisors, Safeguard Scientifics, and SV Life Sciences led the financing round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.